| Version 2.5.2.0 |
|
|
Abstract
Grant Number: 1R43NS060175-01 Project Title: Preclinical Validation of Human Apyrase in Stroke Models
PI Information: Name Title CHEN, RIDONG rchen@niduscenter.com Abstract: DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered a human apyrase, APT102, which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type apyrases. Importantly, APT102 conferred cerebroprotection against experimental stroke without inducing intracerebral hemorrhage. With the Phase I grant support, we will develop a process for high-yield purification of APT102. We will then utilize clinically relevant embolic model to validate whether APT102 provides significant neuroprotective effect without increased bleeding risk. Human apyrase represents a highly promising therapy for acute ischemic stroke. We will utilize a clinically relevant embolic model to validate whether the protein provides significant neuroprotective effect without increased bleeding risk.
Thesaurus Terms:
There are no thesaurus terms on file for this project.
Institution: APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD SAINT LOUIS, MO 63141 Fiscal Year: 2007 Department: Project Start: 01-SEP-2007 Project End: 31-AUG-2008 ICD: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE IRG: ZRG1